Cti Biopharma reported $95.28M in Cash and Equivalent for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Applied Genetic Technologies AGTC:US $ 90.52M 14.54M
Baxter International BAX:US $ 3258M 122M
Bristol Myers Squibb BMY:US $ 13540M 2516M
Cti Biopharma CTIC:US $ 95.28M 23.4M
Cytori Therapeutics CYTX:US $ 21.28M 4.12M
Eli Lilly And LLY:US $ 3788.2M 568.2M
Geron GERN:US $ 29.04M 28.25M
Mirati Therapeutics MRTX:US $ 176.78M 82.21M
Northwest Biotherapeutics NWBO:US 3.84M 78K
Novartis NOVN:VX SF 7211M 2094M
Novartis NVS:US $ 7211M 2094M
Seattle Genetics SGEN:US $ 685.17M 271.74M
Sunesis Pharmaceuticals SNSS:US $ 110.98M 11.74M
Teva Pharmaceutical Industries TEVA:US $ 2045M 391M
YTE INCY:US $ 1999.02M 201.44M